Clovis Withdraws Rubraca Ovarian Cancer Indication Due To Survival Imbalance

OvarianCancer_1200x675
Clovis's timeline for adding to Rubraca's ovarian cancer labeling is uncertain

More from Clinical Trials

More from R&D